Read by QxMD icon Read

New england journal of medicine skin

Jonathan C Dudley, Ming-Tseh Lin, Dung T Le, James R Eshleman
Initial results by Le and colleagues, which were published in the June 25, 2015 issue of the New England Journal of Medicine, report significant responses of cancers with microsatellite instability (MSI) to anti-PD-1 inhibitors in patients who failed conventional therapy. This finding fits into a broader body of research associating somatic hypermutation and neoepitope formation with response to immunotherapy, with the added benefit of relying on a simple, widely used diagnostic test. This review surveys the pathogenesis and prognostic value of MSI, diagnostic guidelines for detecting it, and the frequency of MSI across tumors, with the goal of providing a reference for its use as a biomarker for PD-1 blockade...
February 15, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Kathleen Lee-Sarwar, Anand Vaidya, Min Shi, Cem Akin
New England Journal of Medicine, Volume 372, Issue 26, June 2015.
June 25, 2015: New England Journal of Medicine
L Yilmaz, C Dangoisse, P Semaille
BACKGROUND: In 2008, the New England Journal of Medicine reported a new indication for propranolol: treatment of complicated infantile hemangioma (IH). The objective of this study is to identify any adverse events and to measure the efficacy of propranolol in children with complicated IH, through a retrospective, observational, case-series study of 25 patients treated with propranolol at the Hôpital Universitaire des Enfants Reine Fabiola in Belgium. OBSERVATIONS: 25 patients were submitted to this therapy...
January 2015: Revue Médicale de Bruxelles
Laurent Beaugerie, Steven H Itzkowitz
New England Journal of Medicine, Volume 372, Issue 15, Page 1441-1452, April 2015.
April 9, 2015: New England Journal of Medicine
Lloyd S Miller
New England Journal of Medicine, Volume 372, Issue 14, Page 1368-1370, April 2015.
April 2, 2015: New England Journal of Medicine
Michael R Wessels
New England Journal of Medicine, Volume 372, Issue 12, Page 1164-1165, March 2015.
March 19, 2015: New England Journal of Medicine
Loren G Miller, Robert S Daum, C Buddy Creech, David Young, Michele D Downing, Samantha J Eells, Stephanie Pettibone, Rebecca J Hoagland, Henry F Chambers
BACKGROUND: Skin and skin-structure infections are common in ambulatory settings. However, the efficacy of various antibiotic regimens in the era of community-acquired methicillin-resistant Staphylococcus aureus (MRSA) is unclear. METHODS: We enrolled outpatients with uncomplicated skin infections who had cellulitis, abscesses larger than 5 cm in diameter (smaller for younger children), or both. Patients were enrolled at four study sites. All abscesses underwent incision and drainage...
March 19, 2015: New England Journal of Medicine
George Du Toit, Graham Roberts, Peter H Sayre, Henry T Bahnson, Suzana Radulovic, Alexandra F Santos, Helen A Brough, Deborah Phippard, Monica Basting, Mary Feeney, Victor Turcanu, Michelle L Sever, Margarita Gomez Lorenzo, Marshall Plaut, Gideon Lack
BACKGROUND: The prevalence of peanut allergy among children in Western countries has doubled in the past 10 years, and peanut allergy is becoming apparent in Africa and Asia. We evaluated strategies of peanut consumption and avoidance to determine which strategy is most effective in preventing the development of peanut allergy in infants at high risk for the allergy. METHODS: We randomly assigned 640 infants with severe eczema, egg allergy, or both to consume or avoid peanuts until 60 months of age...
February 26, 2015: New England Journal of Medicine
Oriol Mitjà, Wendy Houinei, Penias Moses, August Kapa, Raymond Paru, Russell Hays, Sheila Lukehart, Charmie Godornes, Sibauk Vivaldo Bieb, Tim Grice, Peter Siba, David Mabey, Sergi Sanz, Pedro L Alonso, Kingsley Asiedu, Quique Bassat
BACKGROUND: Mass treatment with azithromycin is a central component of the new World Health Organization (WHO) strategy to eradicate yaws. Empirical data on the effectiveness of the strategy are required as a prerequisite for worldwide implementation of the plan. METHODS: We performed repeated clinical surveys for active yaws, serologic surveys for latent yaws, and molecular analyses to determine the cause of skin ulcers and identify macrolide-resistant mutations before and 6 and 12 months after mass treatment with azithromycin on a Papua New Guinean island on which yaws was endemic...
February 19, 2015: New England Journal of Medicine
Young M Choi, Aram A Namavar, Jashin J Wu
CONTEXT: General practitioners frequently encounter skin diseases and are accustomed to diagnosing the most common dermatologic conditions. OBJECTIVE: We sought to determine the most common dermatologic topics published in five high-impact general medical journals (New England Journal of Medicine, The Lancet, the Journal of the American Medical Association, British Medical Journal (now The BMJ), and Annals of Internal Medicine). DESIGN: We conducted an independent search of the Thomson Reuters’ Science Citation Index for common dermatologic topics, limited to the period 1970 to 2012...
2014: Permanente Journal
Jakub Tolar, John E Wagner
New England Journal of Medicine, Volume 372, Issue 4, Page 382-384, January 2015.
January 22, 2015: New England Journal of Medicine
Vassiliki A Boussiotis
New England Journal of Medicine, Volume 0, Issue 0, Ahead of Print.
December 4, 2014: New England Journal of Medicine
Alexandra Snyder, Vladimir Makarov, Taha Merghoub, Jianda Yuan, Jesse M Zaretsky, Alexis Desrichard, Logan A Walsh, Michael A Postow, Phillip Wong, Teresa S Ho, Travis J Hollmann, Cameron Bruggeman, Kasthuri Kannan, Yanyun Li, Ceyhan Elipenahli, Cailian Liu, Christopher T Harbison, Lisu Wang, Antoni Ribas, Jedd D Wolchok, Timothy A Chan
BACKGROUND: Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte antigen 4 (CTLA-4). Anti-CTLA-4 treatment prolongs overall survival in patients with melanoma. CTLA-4 blockade activates T cells and enables them to destroy tumor cells. METHODS: We obtained tumor tissue from patients with melanoma who were treated with ipilimumab or tremelimumab...
December 4, 2014: New England Journal of Medicine
Cormac W Joyce, Conor M Sugrue, Kenneth M Joyce, Jack L Kelly, Padraic J Regan
BACKGROUND: Modern immunologic therapies targeting genetic mutations have created a renewed interest in melanoma research, and this is reflected in the increasing number of published works. OBJECTIVE: The purpose of this study was to identify the top 100 most cited articles in melanoma and to examine the characteristics of each individual article. METHODS: Using an electronic database through the Web of Science, we were able to determine the 22 journals that contributed to the 100 most cited articles in melanoma...
December 2014: Dermatologic Surgery: Official Publication for American Society for Dermatologic Surgery [et Al.]
Yanick J Crow, Jean-Laurent Casanova
New England Journal of Medicine, Volume 0, Issue 0, Ahead of Print.
August 7, 2014: New England Journal of Medicine
Y Liu, A A Jesus, B Marrero, D Yang, S E Ramsey, G A Montealegre Sanchez, K Tenbrock, H Wittkowski, O Y Jones, H S Kuehn, C-C R Lee, M A DiMattia, E W Cowen, B Gonzalez, I Palmer, J J DiGiovanna, A Biancotto, H Kim, W L Tsai, A M Trier, Y Huang, D L Stone, S Hill, H J Kim, C St Hilaire, S Gurprasad, N Plass, D Chapelle, I Horkayne-Szakaly, D Foell, A Barysenka, F Candotti, S M Holland, J D Hughes, H Mehmet, A C Issekutz, M Raffeld, J McElwee, J R Fontana, C P Minniti, S Moir, D L Kastner, M Gadina, A C Steven, P T Wingfield, S R Brooks, S D Rosenzweig, T A Fleisher, Z Deng, M Boehm, A S Paller, R Goldbach-Mansky
BACKGROUND: The study of autoinflammatory diseases has uncovered mechanisms underlying cytokine dysregulation and inflammation. METHODS: We analyzed the DNA of an index patient with early-onset systemic inflammation, cutaneous vasculopathy, and pulmonary inflammation. We sequenced a candidate gene, TMEM173, encoding the stimulator of interferon genes (STING), in this patient and in five unrelated children with similar clinical phenotypes. Four children were evaluated clinically and immunologically...
August 7, 2014: New England Journal of Medicine
Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, Rory Collins, Jane Armitage
BACKGROUND: Patients with evidence of vascular disease are at increased risk for subsequent vascular events despite effective use of statins to lower the low-density lipoprotein (LDL) cholesterol level. Niacin lowers the LDL cholesterol level and raises the high-density lipoprotein (HDL) cholesterol level, but its clinical efficacy and safety are uncertain. METHODS: After a prerandomization run-in phase to standardize the background statin-based LDL cholesterol-lowering therapy and to establish participants' ability to take extended-release niacin without clinically significant adverse effects, we randomly assigned 25,673 adults with vascular disease to receive 2 g of extended-release niacin and 40 mg of laropiprant or a matching placebo daily...
July 17, 2014: New England Journal of Medicine
Lisa A Beck, Diamant Thaçi, Jennifer D Hamilton, Neil M Graham, Thomas Bieber, Ross Rocklin, Jeffrey E Ming, Haobo Ren, Richard Kao, Eric Simpson, Marius Ardeleanu, Steven P Weinstein, Gianluca Pirozzi, Emma Guttman-Yassky, Mayte Suárez-Fariñas, Melissa D Hager, Neil Stahl, George D Yancopoulos, Allen R Radin
BACKGROUND: Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The blockade by dupilumab of these key drivers of type 2 helper T-cell (Th2)-mediated inflammation could help in the treatment of related diseases, including atopic dermatitis. METHODS: We performed randomized, double-blind, placebo-controlled trials involving adults who had moderate-to-severe atopic dermatitis despite treatment with topical glucocorticoids and calcineurin inhibitors...
July 10, 2014: New England Journal of Medicine
Henry F Chambers
New England Journal of Medicine, Volume 370, Issue 23, Page 2238-2239, June 2014.
June 5, 2014: New England Journal of Medicine
G Ralph Corey, Heidi Kabler, Purvi Mehra, Sandeep Gupta, J Scott Overcash, Ashwin Porwal, Philip Giordano, Christopher Lucasti, Antonio Perez, Samantha Good, Hai Jiang, Greg Moeck, William O'Riordan
BACKGROUND: Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria. Its concentration-dependent activity and prolonged half-life allow for single-dose treatment. METHODS: We conducted a randomized, double-blind trial in which adults with acute bacterial skin and skin-structure infections received either a single intravenous dose of 1200 mg of oritavancin or a regimen of intravenous vancomycin twice daily for 7 to 10 days. Three efficacy end points were tested for noninferiority...
June 5, 2014: New England Journal of Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"